In two children with recurrent parotitis, labial salivary gland biopsies showed chronic sialoadenitis. Immunofluorescence studies disclosed deposits of immunoglobulins and complement in juxta-acinar small vessels. Case 1 had gluten enteropathy, IgA deficiency and high titres of antinuclear antibodies (ANA), and in vivo fixation of ANA to nuclei of different cells in lip, skin and jejunum was present. Case 2 showed deposition of IgM in the dermo-epidermal junction of the skin. These findings suggest that autoimmune reactivity and immune complexes may play a role in the pathogenesis of this disorder.

In a prospective study of 129 women undergoing induced first-trimester abortion, 14 (10.9%) contracted postabortal pelvic inflammatory disease (PID). Samples of vaginal secretion for quantitation of secretory immunoglobulin A (sIgA) as well as isolates from cervix/urethra for the culture of anaerobes and aerobes, including Bacteroides fragilis et melaninogenicus and Gardnerella vaginalis, were obtained at the preoperative visit. Two blood samples from each woman with postabortal PID were analysed for antibodies against G. vaginalis. Twenty-five per cent of women with a history of PID developed postabortal PID, and 25% with vaginitis contracted postabortal infection (p less than 0.001 and p less than 0.005). Twenty-five per cent of women harboring C. trachomatis at the time of abortion developed infection. The presence of anaerobes or G. vaginalis was not associated with the frequency of postabortal PID (all p-values greater than 0.1). One woman with postabortal PID produced a culture positive for G. vaginalis and a rise in specific antibody titer. The levels of vaginal sIgA were not significantly associated with a positive history of PID (p greater than 0.6), with postabortal PID (p greater than 0.4) or with the presence of anaerobes or G. vaginalis at the time of abortion (p greater than 0.3). However, significantly elevated levels of sIgA were found in women harboring C. trachomatis (p less than 0.05). Thus, the study could not demonstrate any correlation between vaginal sIgA and PID, but increased sIgA in Chlamydia-positive women. A history of PID and vaginitis entailed a significant risk of contracting postabortal PID.

ObjectivesGenotypic interpretation systems extrapolate observed associations in datasets to predict viral susceptibility to antiretroviral drugs (ARVs) for given isolates. We aimed to develop and validate an approach using artificial neural networks (ANNs) that employ descriptors of physiochemical properties for mutations in HIV-1 protease (PR) and reverse transcriptase (RT) to predict phenotypic susceptibility to all currently approved ARVs. MethodWe extracted pairs of PR and RT gene sequences (n 5 1507; 98.5% sub-type B) and their corresponding exact phenotype values (PhenoSense only, n 5 10 132) from the Stanford HIV database. All amino acid positions and mixture codes were accounted for. For each ARV, an ANN was trained with 10-fold internal cross-validation. The predictive abilities of these trained ANNs were validated on separate datasets. ConclusionsANNs, based on the physiochemical properties of the PR and RT amino-acid sequences, predict phenotypic susceptibility to ARVs inhibiting these enzymes to an extent that is comparable to routine phenotypic susceptibility testing. These ANNs can also be used to predict resistance to C sub-types.

In a randomized clinical study, 32 patients with Sögren's syndrome (SS were given placebo/bromhexine (Bisolvon) 48 mg daily for 3 weeks. Various ophthalmological and oral variables as well as different proteins in the tear fluid and saliva were registered. Bromhexine stimulated the tear secretion significantly, presumable without changing the protein composition of the tear fluid. In contrast to other proteins in saliva the IgM concentration decreased in patients with high pre-treatment values. Bromhexine may be of valuable help in the treatment of some patients with SS.

The findings in ulcerative colitis of increased histamine content in the colonic mucosa, particularly in patients with eosinophilia,3 further supported the possibility that DSCG, by its ability to stabilise the mast cells, would have a beneficial effect on patients with inflammatory bowel diseases or at least on some of the patients.In view of these findings we decided in April 1977 to start a controlled double-blind study of DSCG versus placebo. The aims of the study were (1) to determine the effect on patients in an active stage of ulcerative colitis-that is, the curative effect-and (2) to determine its effect in preventing relapses in clinically inactive patients with ulcerative colitis and Crohn's disease-that is, the prophylactic effect.